頭頸部扁平上皮癌:治療薬開発パイプライン動向(2016年下半期版)

Global Markets Directが発行した調査報告書(DATA70209318)
◆英語タイトル:Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016
◆商品コード:DATA70209318
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年11月9日
◆ページ数:722
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における頭頸部扁平上皮癌の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・頭頸部扁平上皮癌の概要
・頭頸部扁平上皮癌治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・頭頸部扁平上皮癌パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・頭頸部扁平上皮癌治療薬開発に取り組んでいる企業:企業別製品パイプライン
・頭頸部扁平上皮癌治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H2 2016, provides an overview of the Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline landscape.

Head and Neck Cancer Squamous Cell Carcinoma is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 49, 49, 2, 23, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 4 and 2 molecules, respectively.Head And Neck Cancer Squamous Cell Carcinoma.

Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head And Neck Cancer Squamous Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer Squamous Cell Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 6
Head And Neck Cancer Squamous Cell Carcinoma Overview 7
Therapeutics Development 8
Head And Neck Cancer Squamous Cell Carcinoma – Therapeutics under Development by Companies 10
Head And Neck Cancer Squamous Cell Carcinoma – Therapeutics under Investigation by Universities/Institutes 17
Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Products Glance 18
Head And Neck Cancer Squamous Cell Carcinoma – Products under Development by Companies 22
Head And Neck Cancer Squamous Cell Carcinoma – Products under Investigation by Universities/Institutes 32
Head And Neck Cancer Squamous Cell Carcinoma – Companies Involved in Therapeutics Development 33
Head And Neck Cancer Squamous Cell Carcinoma – Therapeutics Assessment 118
Drug Profiles 148
Head And Neck Cancer Squamous Cell Carcinoma – Dormant Projects 682
Head And Neck Cancer Squamous Cell Carcinoma – Discontinued Products 687
Head And Neck Cancer Squamous Cell Carcinoma – Product Development Milestones 689
Appendix 704

List of Tables
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2016 25
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2016 26
Number of Products under Development by Companies, H2 2016 27
Number of Products under Development by Companies, H2 2016 (Contd..1) 28
Number of Products under Development by Companies, H2 2016 (Contd..2) 29
Number of Products under Development by Companies, H2 2016 (Contd..3) 30
Number of Products under Development by Companies, H2 2016 (Contd..4) 31
Number of Products under Development by Companies, H2 2016 (Contd..5) 32
Number of Products under Development by Companies, H2 2016 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H2 2016 34
Comparative Analysis by Late Stage Development, H2 2016 35
Comparative Analysis by Clinical Stage Development, H2 2016 36
Comparative Analysis by Early Stage Development, H2 2016 37
Comparative Analysis by Unknown Stage Development, H2 2016 38
Products under Development by Companies, H2 2016 39
Products under Development by Companies, H2 2016 (Contd..1) 40
Products under Development by Companies, H2 2016 (Contd..2) 41
Products under Development by Companies, H2 2016 (Contd..3) 42
Products under Development by Companies, H2 2016 (Contd..4) 43
Products under Development by Companies, H2 2016 (Contd..5) 44
Products under Development by Companies, H2 2016 (Contd..6) 45
Products under Development by Companies, H2 2016 (Contd..7) 46
Products under Development by Companies, H2 2016 (Contd..8) 47
Products under Development by Companies, H2 2016 (Contd..9) 48
Products under Investigation by Universities/Institutes, H2 2016 49
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AB Science SA, H2 2016 50
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AbbVie Inc, H2 2016 51
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Accelerated Pharma, Inc., H2 2016 52
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016 53
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 54
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H2 2016 55
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Altor BioScience Corporation, H2 2016 56
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2016 57
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H2 2016 58
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 59
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bayer AG, H2 2016 60
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bionovis SA, H2 2016 61
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by BioNTech AG, H2 2016 62
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 63
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 64
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H2 2016 65
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H2 2016 66
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016 67
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 68
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Centrose LLC, H2 2016 69
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H2 2016 70
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CytImmune Sciences, Inc., H2 2016 71
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 72
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016 73
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eleven Biotherapeutics Inc., H2 2016 74
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016 75
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Etubics Corporation, H2 2016 76
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 77
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016 78
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GeneSegues Inc, H2 2016 79
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H2 2016 80
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genmab A/S, H2 2016 81
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016 82
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H2 2016 83
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2016 84
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 85
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016 86
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunomedics, Inc., H2 2016 87
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2016 88
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016 89
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 90
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Innate Pharma S.A., H2 2016 91
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 92
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by IRX Therapeutics, Inc., H2 2016 93
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Johnson & Johnson, H2 2016 94
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 95
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H2 2016 96
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Loxo Oncology, Inc., H2 2016 97
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H2 2016 98
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MacroGenics, Inc., H2 2016 99
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Marsala Biotech Inc., H2 2016 100
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mateon Therapeutics Inc, H2 2016 101
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune LLC, H2 2016 102
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016 103
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck KGaA, H2 2016 104
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 105
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 106
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H2 2016 107
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molecular Partners AG, H2 2016 108
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Molplex Ltd., H2 2016 109
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by NanoCarrier Co., Ltd., H2 2016 110
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2016 111
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016 112
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2016 113
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2016 114
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OncoSec Medical Incorporated, H2 2016 115
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 116
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2016 117
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech Holding ASA, H2 2016 118
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016 119
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016 120
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sanofi, H2 2016 121
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 122
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2016 123
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016 124
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H2 2016 125
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by SynCore Biotechnology Co., Ltd., H2 2016 126
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H2 2016 127
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 128
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Transgene SA, H2 2016 129
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by UbiVac, LLC, H2 2016 130
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VasGene Therapeutics, Inc., H2 2016 131
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 132
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H2 2016 133
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Vyriad Inc, H2 2016 134
Assessment by Monotherapy Products, H2 2016 135
Assessment by Combination Products, H2 2016 136
Number of Products by Stage and Target, H2 2016 138
Number of Products by Stage and Mechanism of Action, H2 2016 150
Number of Products by Stage and Route of Administration, H2 2016 162
Number of Products by Stage and Molecule Type, H2 2016 164
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2016 699
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..1), H2 2016 700
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..2), H2 2016 701
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..3), H2 2016 702
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects (Contd..4), H2 2016 703
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2016 704
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products (Contd..1), H2 2016 705

List of Figures
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2016 25
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2016 26
Number of Products under Development by Companies, H2 2016 27
Number of Products under Investigation by Universities/Institutes, H2 2016 34
Comparative Analysis by Late Stage Development, H2 2016 35
Comparative Analysis by Clinical Stage Development, H2 2016 36
Comparative Analysis by Early Stage Products, H2 2016 37
Assessment by Monotherapy Products, H2 2016 135
Assessment by Combination Products, H2 2016 136
Number of Products by Top 10 Targets, H2 2016 137
Number of Products by Stage and Top 10 Targets, H2 2016 137
Number of Products by Top 10 Mechanism of Actions, H2 2016 149
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 149
Number of Products by Top 10 Routes of Administration, H2 2016 161
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 161
Number of Products by Top 10 Molecule Types, H2 2016 163
Number of Products by Stage and Top 10 Molecule Types, H2 2016 163

【レポートのキーワード】

頭頸部扁平上皮癌

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 頭頸部扁平上皮癌:治療薬開発パイプライン動向(2016年下半期版)(Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆